on June 5, 2006
Published online before print June 5, 2006, doi: 10.1161/CIRCULATIONAHA.105.577577
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on July 21, 2005
From the Division of Research, Kaiser Permanente of Northern California, Oakland (A.S.G., J.Y., L.M.A., K.L.); the Departments of Epidemiology and Biostatistics (A.S.G., L.M.A., M.G.S.) and of Medicine (A.S.G., B.M.M., M.G.S.), University of California at San Francisco; Amgen, Thousand Oaks (S.R.); and the Cardiology (B.M.M.) and General Internal Medicine (M.G.S.) Sections, San Francisco Veterans Affairs Medical Center, San Francisco, Calif. * To whom correspondence should be addressed. E-mail: Alan.S.Go{at}kp.org.
Background--Previous studies have associated reduced hemoglobin levels with increased adverse events in heart failure. It is unclear, however, whether this relation is explained by underlying kidney disease, treatment differences, or associated comorbidity. Methods and Results--We examined the associations between hemoglobin level, kidney function, and risks of death and hospitalization in persons with chronic heart failure between 1996 and 2002 within a large, integrated, healthcare delivery system in northern California. Longitudinal outpatient hemoglobin and creatinine levels and clinical and treatment characteristics were obtained from health plan records. Glomerular filtration rate (GFR; mL · min-1 · 1.73 m-2) was estimated from the Modification of Diet in Renal Disease equation. Mortality data were obtained from state death files; heart failure admissions were identified by primary discharge diagnoses. Among 59 772 adults with heart failure, the mean age was 72 years and 46% were women. Compared with that for hemoglobin levels of 13.0 to 13.9 g/dL, the multivariable-adjusted risk of death increased with lower hemoglobin levels: an adjusted hazard ratio (HR) of 1.16 and 95% confidence interval (CI) of 1.11 to 1.21 for hemoglobin levels of 12.0 to 12.9 g/dL; HR, 1.50 and 95% CI, 1.44 to 1.57 for 11.0 to 11.9 g/dL; HR, 1.89 and 95% CI, 1.80 to 1.98 for 10.0 to 10.9; HR, 2.31 and 95% CI, 2.18 to 2.45 for 9.0 to 9.9; and HR, 3.48 and 95% CI, 3.25 to 3.73 for <9.0 g/dL. Hemoglobin levels Conclusions--Very high (
Revised on March 7, 2006
Accepted on April 4, 2006
Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure. The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study
Alan S. Go MD*,
17.0 g/dL were associated with an increased risk of death (adjusted HR, 1.42; 95% CI, 1.24 to 1.63). Compared with those with a GFR 60 mL · min-1 · 1.73 m-2, persons with a GFR <45 mL · min-1 · 1.73 m-2 had an increased mortality risk: adjusted HR, 1.39 and 95% CI, 1.34 to 1.44 for 30 to 44; HR, 2.28 and 95% CI, 2.19 to 2.39 for 15 to 29; HR, 3.26 and 95% CI, 3.05 to 3.49 for <15; and HR, 2.44 and 95% CI, 2.28 to 2.61 for those on dialysis. Relations were similar for the risk of hospitalization. The findings did not differ among patients with preserved or reduced systolic function, and hemoglobin level was an independent predictor of outcomes at all levels of kidney function.17 g/dL) or reduced (<13 g/dL) hemoglobin levels and chronic kidney disease independently predict substantially increased risks of death and hospitalization in heart failure, regardless of the level of systolic function. Randomized trials are needed to evaluate whether raising hemoglobin levels can improve outcomes in chronic heart failure.
Key words: anemia • death • epidemiology • heart failure • hemoglobin • hospitalization • kidney
Related Article:
Circulation 2006 113: 2675.
This article has been cited by other articles:
 |
|
 |
|
  K. Dimopoulos, G.-P. Diller, G. Giannakoulas, R. Petraco, A. Chamaidi, E. Karaoli, M. Mullen, L. Swan, M. F. Piepoli, P. A. Poole-Wilson, et al. Anemia in Adults With Congenital Heart Disease Relates to Adverse Outcome J. Am. Coll. Cardiol., November 24, 2009; 54(22): 2093 - 2100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. van der Meer and D. J van Veldhuisen Anaemia and renal dysfunction in chronic heart failure Heart, November 1, 2009; 95(21): 1808 - 1812. [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Mielniczuk, M. A. Pfeffer, E. F. Lewis, M. A. Blazing, J. A. de Lemos, S. Mohanavelu, J. Rouleau, K. Fox, T. R. Pedersen, and R. M. Califf Acute Decline in Renal Function, Inflammation, and Cardiovascular Risk after an Acute Coronary Syndrome Clin. J. Am. Soc. Nephrol., November 1, 2009; 4(11): 1811 - 1817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-J. Kim, D.-A Kwon, H.-K. Kim, J.-S. Park, S. Hahn, K.-H. Kim, K.-B. Kim, D.-W. Sohn, H. Ahn, B.-H. Oh, et al. Determinants of Surgical Outcome in Patients With Isolated Tricuspid Regurgitation Circulation, October 27, 2009; 120(17): 1672 - 1678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Besarab, W. H. Horl, and D. Silverberg Iron Metabolism, Iron Deficiency, Thrombocytosis, and the Cardiorenal Anemia Syndrome Oncologist, September 1, 2009; 14(suppl_1): 22 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kalantar-Zadeh and G. R. Aronoff Hemoglobin Variability in Anemia of Chronic Kidney Disease J. Am. Soc. Nephrol., March 1, 2009; 20(3): 479 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Pagourelias, C. Koumaras, A. I. Kakafika, K. Tziomalos, P. G. Zorou, V. G. Athyros, and A. Karagiannis Cardiorenal Anemia Syndrome: Do Erythropoietin and Iron Therapy Have a Place in the Treatment of Heart Failure? Angiology, February 1, 2009; 60(1): 74 - 81. [Abstract] [PDF]
|
|
|
|
|
|
A. Hakeem, S. Bhatti, K. S. Dillie, J. R. Cook, Z. Samad, M. D. Roth-Cline, and S. M. Chang Predictive Value of Myocardial Perfusion Single-Photon Emission Computed Tomography and the Impact of Renal Function on Cardiac Death Circulation, December 9, 2008; 118(24): 2540 - 2549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Go, J. Yang, J. H. Gurwitz, J. Hsu, K. Lane, and R. Platt Comparative Effectiveness of Different {beta}-Adrenergic Antagonists on Mortality Among Adults With Heart Failure in Clinical Practice Arch Intern Med, December 8, 2008; 168(22): 2415 - 2421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. F. Groenveld, J. L. Januzzi, K. Damman, J. van Wijngaarden, H. L. Hillege, D. J. van Veldhuisen, and P. van der Meer Anemia and Mortality in Heart Failure Patients: A Systematic Review and Meta-Analysis J. Am. Coll. Cardiol., September 2, 2008; 52(10): 818 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. S. Anand Anemia and Chronic Heart Failure: Implications and Treatment Options J. Am. Coll. Cardiol., August 12, 2008; 52(7): 501 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Henkel, M. M. Redfield, S. A. Weston, Y. Gerber, and V. L. Roger Death in Heart Failure: A Community Perspective Circ Heart Fail, July 1, 2008; 1(2): 91 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.H. W. Tang, W. Tong, A. Jain, G. S. Francis, C. M. Harris, and J. B. Young Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J. Am. Coll. Cardiol., February 5, 2008; 51(5): 569 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Husemann, M. Fobker, M. Pohlen, C. Bruch, M. Hausberg, G. Breithardt, and H. Reinecke Impact of haemoglobin concentration and chronic kidney disease in patients with coronary heart disease undergoing percutaneous coronary interventions Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2563 - 2570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Desai, K. Bibbins-Domingo, M. G. Shlipak, A. H.B. Wu, S. Ali, and M. A. Whooley Association between anaemia and N-terminal pro-B-type natriuretic peptide (NT-proBNP): Findings from the Heart and Soul Study Eur J Heart Fail, September 1, 2007; 9(9): 886 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. C. Dowling Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: An overview Am. J. Health Syst. Pharm., July 1, 2007; 64(13_Supplement_8): S3 - S7. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Inglis, S. Stewart, A. Papachan, V. Vaghela, C. Libhaber, Y. Veriava, and K. Sliwa Anaemia and renal function in heart failure due to idiopathic dilated cardiomyopathy Eur J Heart Fail, April 1, 2007; 9(4): 384 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Andreotti, G. Coluzzi, and F. Crea Letter by Andreotti et al Regarding Article, "Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study" Circulation, March 6, 2007; 115(9): e313 - e313. [Full Text] [PDF]
|
|
|
|
|
|
A. S. Go, J. Yang, L. M. Ackerson, K. Lepper, M. G. Shlipak, S. Robbins, and B. M. Massie Response to Letter Regarding Article, "Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study" Circulation, March 6, 2007; 115(9): e314 - e314. [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Go, W. Y. Lee, J. Yang, J. C. Lo, and J. H. Gurwitz Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA, November 1, 2006; 296(17): 2105 - 2111. [Abstract] [Full Text] [PDF]
|
|